VR Adviser’s ALX Oncology ALXO Stock Holding History

VR Adviser’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300,000	Closed	-$11.3M	–	26
2020 Q3	$11.3M	Buy	+300,000	New	+$11.8M	2.21%	15

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VR Adviser's ALXO Position: Q4 2020 in Review

VR Adviser sold out of ALX Oncology (ALXO) in Q4 2020, closing a stake of 300,000 shares — an estimated $11.3M sold.

VR Adviser first reported a position in ALXO in Q3 2020 and held it in 1 quarter. The position peaked at $11.3M in Q3 2020. 89 funds tracked by Wall St. Rank hold ALXO as of Q4 2020.

VR Adviser reported no remaining ALX Oncology position as of Q4 2020 after selling out during the quarter.
VR Adviser sold 300,000 ALX Oncology shares in Q4 2020, an estimated $11.3M.
VR Adviser first reported a position in ALX Oncology in Q3 2020 and held it in 1 quarter.
VR Adviser's ALX Oncology position peaked at $11.3M in Q3 2020.
89 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2020.

Based on VR Adviser's 13F filing for Q4 2020, filed 12 Feb 2021.